Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Fredrik Wetterlundh as Head of Human Resources. Fredrik will join Sobi on 9 April 2018 and be part of Sobi’s Extended Leadership Team.
Fredrik Wetterlundh joins Sobi from Pfizer, where he held the position of Global Human Resources Lead in Pfizer’s Global Supply organisation. He has extensive international experience in leading business-driven HR organisations, processes and projects in Asia, Europe, and North and Central America, and has supported a number of successful mergers and acquisitions and divestitures. Fredrik holds a degree in HR Management from the University of Lund, Sweden.
Guido Oelkers, CEO and President of Sobi, sees the appointment as a valuable addition to the company. “His experience from the pharmaceutical industry, numerous company integrations and the global roles he has held will be of great value for Sobi, supporting our organisation and our journey to become a global leader in rare diseases,” he said.
Fredrik says he is excited to be joining Sobi. “Sobi is a value-driven company with highly experienced employees and a strong culture. These are valuable assets to build on. I look forward to contributing to Sobi’s growth strategy with my experience in implementing effective organisation and people strategies,” he said.
Source: Sobi™
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
